MiniMed Insulin Pump:

Size: px
Start display at page:

Download "MiniMed Insulin Pump:"

Transcription

1 MiniMed for TYPE MiniMed Insulin Pump: DIABETES Significant HbA1c reduction for type 2 diabetes, now clinically proven 1

2 Do your type 2 patients, despite a multiple daily injection () regimen and active insulin titration, still face challenges in meeting HbA1c targets? Is not well managed and not fulfilling your patients needs? Discover how MiniMed pump could help. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use

3 The OpT2mise study 2 The Medtronic-sponsored OpT2mise study is the largest (331 patients) randomized, controlled trial on insulin pump therapy for type 2 diabetes. This international, multicenter (36 centers around the globe), parallel-group study consisted of a run-in period, a six-month randomized phase and a six-month continuation phase. EFFICACY This study provides a compelling case for the clinical effectiveness of CSII [continuous subcutaneous insulin infusion] in type 2 diabetes, suggesting that it can help improve glycemic control in this difficult cohort of patients with poor control despite efforts at increasing insulin dose. Although other options such as GLP-1RA [glucagon-like peptide 1-receptor agonists] and bariatric surgery are available, these will be unsuitable or not tolerated by a significant proportion of patients. In these patients, CSII offers a higher chance of optimization of glucose control and should be considered as a viable and effective option. Dr Pratik Choudhary, Diabetes Research Group, King s College London, Weston Education Centre, London, UK Extract from Continuous subcutaneous insulin infusion for type 2 diabetes, comment to The Lancet article, 3rd July 2014 OTHER RESULTS 1.1 % 1.1 % HbA1c drop with MiniMed insulin pump therapy versus a 0.4% drop in the group on 20.4% LOWER COMPARED WITH -20% total daily insulin dose reduction with MiniMed insulin pump therapy when compared with % 0.7 % between groups difference in HbA1c in favor of MiniMed insulin pump therapy +8 % +8% increase of HDL-cholesterol concentration with MiniMed insulin pump therapy and -7% decrease in the group 331 patients 36 centers around the globe Study Schedule 3 Run-in Optimization Randomization Treatment: CSII Control: 2 6 Study phase 6 months Continuation phase 6 months Single Arm Cross to CSII Mean A1C and 95% C.I. (%) X2 Run-in (8 weeks) Baseline 9.0% Study Phase (6 months + 3 weeks) CSII 8.6% CSII 7.9% Week Almost twice as many patients achieve HbA1C < 8% with MiniMed insulin pump therapy Patients that achieved HbA1c <8% NO SIGNIFICANT DIFFERENCE SAFETY No significant difference in body weight change with MiniMed insulin pump therapy No severe hypoglycemia event with MiniMed insulin pump therapy and no increase in the time spent in hypoglycemia No ketoacidosis event with MiniMed insulin pump therapy POTENTIAL LONG-TERM BENEFIT Reducing HbA1c is critical for people with diabetes. Month The study results The study concluded that MiniMed Pump Therapy can significantly improve glycemic control, compared with strategies, in patients with T2 diabetes who are unable to reach glycated haemoglobin goals. 4 MiniMed Pump Therapy has been proven to be effective and safe: it might therefore be considered a valuable therapeutic option in this population Patient group on 55% 28% MiniMed insulin pump therapy MiniMed insulin pump therapy is clinically proven to reduce HbA1c better than multiple daily injections for people with type 2 diabetes suboptimally controlled 1 Patient group on Multiple Daily Injections () 1.1% drop in HbA1c is associated with significant reduction in diabetes-related complications such as eye disease, kidney disease, nerve damage and heart attacks 3,4 Risk Reduction (%) Microvascular -37% Any Endpoint Related to Diabetes Death Related to Diabetes -21% -21% Fatal and Non-fatal Myocardial infarction -14% UKPDS: United Kingdom Prospective Diabetes Study. UKPDS: United Kingdom Prospective Diabetes Study; MI: myocardial infarction; PVD: peripheral vascular disease. Amputation or Death from peripheral vascular disease -43%

4 20 % More than 20% of people taking insulin with admit that injections interfere with their daily life, creating anxiety and discomfort % of people taking insulinwith openly admit to omittinginsulin injections. 5 Meet John and Janis, type 2 diabetes patients and discover how their lives have been changed thanks to the MiniMed Pump. PROFILE Janis IN BETTER CONTROL WITH MINIMED PUMP SINCE 2009 The MiniMed pump has been wonderful for me. It keeps my numbers down and I can do whatever I want to do. It gives me freedom and better control My glycated hemoglobin has improved. Today, on MiniMed pump therapy, is 6.4%. It was 9.1% on multiple daily injections Type 2 candidates for MiniMed insulin pump therapy Your type 2 patients on therapy might be candidates for MiniMed pump therapy if: 2009 I am in better control with my MiniMed pump since 2009, when I made the switch from multiple daily injections Patient clinical profile: HbA1c between 8% -12% I nsulin requirements of U/kg Multiple daily injections therapy (3+ injections per day) with or without combination with other oral or non-insulin injectable agents Facing challenges to meet HbA1c goals despite dosing titrations over at least the last 3 months Patient behavioral parameters: Patient shows dissatisfaction and/or difficulty adhering to current medication regimen He/She has an active life and finds it difficult to fulfill the requirements of He/She often forgets to bolus at meals and can t follow a regular diet regimen He/She is motivated and willing to monitor blood glucose since concerned about long-term complications A better glucose control has positive long-term health consequences on diabetes burden including cardiovascular and diabetes-related microvascular complications. Our findings open up a valuable new treatment option for those individuals failing on current injection regimens and may also provide improved convenience, reducing the burden of dose tracking and scheduling, and decreasing insulin injection omissions. Prof. Yves Reznik, OpT2mise investigator, Department of Endocrinology, University of Caen Côte de nacre Regional Hospital Center, Caen, France PROFILE John IN BETTER CONTROL WITH MINIMED PUMP SINCE Using the MiniMed pump has allowed me to get tighter control of my blood glucose levels with less interaction in dealing with taking multiple daily injections and oral medications My glycated hemoglobin has improved. Today, on MiniMed pump therapy, is between the range 6.2% - 7.2%. It was 9.2% on multiple daily injections. I have reduced my daily insulin intake to 170 units. It was 220 units on multiple daily injections I am in better control with my MiniMed pump since 2013, when I made the switch from multiple daily injections In the OpT2mise study, older age, longer duration of diabetes, low cognitive score and low SMBG use did not diminish the positive effect of CSII therapy 6

5 Patients treatment satisfaction 7 Patients using MiniMed Pump therapy reported increased satisfaction of diabetes treatment with significant improvements in: treatment convenience flexibility understanding of diabetes willingness to recommend the treatment satisfaction to continue treatment 6 5 p<0.05 p< p< p<0.05 p< p< CSII Scale 0 to Overall Satisfaction Treatment convenience Flexibility Understanding Willingness to of diabetes Recommend the Treatment Satisfaction to Continue the Treatment p< NS Perceived Perceived Hyperglycemia Hypoglycemia MiniMed insulin pump therapy provides better control 1 and is easy to learn and use, which may lead to improved patient satisfaction and better adherence to your therapy plan. MiniMed pump therapy can help reduce patients anxiety and discomfort of insulin taking. This can improve their adherence to therapy MiniMed pump: convenient therapy management for your type 2 patients You may think your type 2 patients aren t qualified for insulin pump therapy. The truth, however, is that it can be less demanding than taking multiple daily injections. For example, OpT2mise study also demonstrated that even the subgroup of patients with mild cognitive impairments experienced benefit in HbA1c reduction similar to general population by using MiniMed pump therapy*. Only 10 to 12 infusion set changes instead of up to injections per month Meal time insulin is delivered painlessly and discreetly with a few simple button presses. Anywhere and in every situation today is not always providing an ideal solution for all type 2 patients. Pump therapy with MiniMed pump has improved control for these patients. For years it has been common thought that pump would apply to type 1 patients only. OpT2mise study results instead show that the pump could be a good option and effective tool for type 2 patients as well. Patients acceptance of the pump was excellent. After the study, most of them did not want to go back to Prof. Ohad Cohen, OpT2mise investigator, Institute of Endocrinology, Chaim Sheba Medical Center, Tel Hashomer, Israel MiniMed 640G features to adapt to type 2 diabetes therapy High insulin needs With 3ml/300 units capacity, usage of insulin reservoir is maximized and changes minimized. Max bolus of 75 units to meet also high insulin needs combined with High bolus speed (15 units/minute. Max bolus delivered in 5 minutes) Multiple basal rates to best meet their insulin needs Simplicity & support Up to 8 Preset Bolus amounts, easy to access and deliver The Missed Meal Bolus Reminder will help to ensure that your patients don t miss a dose. Convenience and discretion Possible to deliver an insulin bolus discreetly from Bayer Contour Next LINK 2.4 meter or on the pump with few simple button pushes Volume adjustable for alarms and vibration mode available Full color screen Self adjusting display that adapt to light If your patient suffers from DEXTERITY IMPAIRMENT, this feature could be useful Key pad with tactile recognizable button and usable by both right and left handed *At baseline, 64 (38%) patients in the pump treatment group and 64 (39%) in the multiple injection group had abnormal scores on the Montreal Cognitive Assessment test, indicative of mild cognitive impairment. Both groups had a similar fall in glycated haemoglobin and a similar increase in total insulin daily dose during the run-in period 1.

6 MiniMed for TYPE DIABETES Getting2Goal SM Type 2 Diabetes Pumping Protocol A simplified approach to insulin pump therapy for patients with type 2 diabetes Convenient for your practice With the Type 2 Pumping Protocol Getting 2 Goal SM, MiniMed insulin pump therapy can be made simple and convenient for you and your diabetes care team, with options to advance therapy if desired. It provides a simplified approach for initiating insulin pump therapy. A flexible approach to bolus options and multiple basal rates allows a customized approach for your patients, based on their individual needs. CareLink Pro provides easy-to-interpret trend reports for glycemic data and behavior patterns. Take the guess work out of your patients compliance to their prescribed regimen. Evaluate their compliance to insulin therapy via CareLink reports. Give your type 2 patients the opportunity for a better control. Evaluate with them the therapy with MiniMed pump. Why MiniMed? For over 25 years, Medtronic has offered products with unique features and support, confirming leadership in innovation in insulin pump therapy and integrated system and always having patients needs as first priority. Customer support and service to help improve the quality of your practice and outcomes for your patients. Education and training programs for patients and HCPs. CareLink : CareLink Pro provides easy-to-interpret trend reports for glycemic data and behavior patterns.

7 References 1. Reznik Y. Cohen O. Aronson R. et al. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open label controlled trial. Lancet 2014 Volume 384, Issue 9950, P , 4 October Aronson R, Cohen O, Conget I, et al. OpT2mise: A Randomized Controlled Trial to Compare Insulin Pump Therapy with Multiple Daily Injections in the Treatment of Type 2 Diabetes-Research Design and Methods. Diabetes Technol Ther 2014 Jul;16(7): doi: /dia Epub 2014 Apr Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 Sep 12;352(9131): Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 Oct 9; 359(15): Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care, 2010 Feb;33(2): Factors associated with successful continuous subcutaneous insulin infusion therapy in type 2 diabetes patients - the OPT2MISE trial - Cohen at al. Presented at EASD OpT2mise study: The Impact of Insulin Pump Therapy on Treatment Satisfaction and Resource Utilization in Patients with Type 2 Diabetes Aronson et al. Presented at EASD Europe Medtronic International Trading Sàrl. Route du Molliau 31 Case postale CH-1131 Tolochenaz Tel: +41 (0) Fax: +41 (0) United Kingdom/Ireland Medtronic UK Ltd. Building 9 Croxley Green Business Park Watford Hertfordshire WD18 8WW UK Tel: +44 (0) Fax: +44 (0) MiniMed, Veo and CareLink are registered trademarks of Medtronic MiniMed, Inc. UC EE 2014 Medtronic International Trading Sarl. All Rights Reserved. No part of this brochure may be reproduced or utilized in any form or by any means without the written permission of Medtronic International Trading Sarl. Printed in Europe.

WHAT CAN I DO TO REDUCE MY RISK OF DEVELOPING THE COMPLICATIONS OF TYPE 1 DIABETES?

WHAT CAN I DO TO REDUCE MY RISK OF DEVELOPING THE COMPLICATIONS OF TYPE 1 DIABETES? Christian In better control with his pump since 2012 WHAT CAN I DO TO REDUCE MY RISK OF DEVELOPING THE COMPLICATIONS OF TYPE 1 DIABETES? Many people with Type 1 diabetes worry about potential long-term

More information

I HAVE JUST BEEN DIAGNOSED WITH TYPE 1 DIABETES

I HAVE JUST BEEN DIAGNOSED WITH TYPE 1 DIABETES Dominika In better control with her pump since 2012 I HAVE JUST BEEN DIAGNOSED WITH TYPE 1 DIABETES The diagnosis of Type 1 diabetes may come as a shock and may lead to many questions, such as: Why is

More information

Anneli, Martina s daughter In better control with her pump since 2011 MY CHILD HAS TYPE 1 DIABETES

Anneli, Martina s daughter In better control with her pump since 2011 MY CHILD HAS TYPE 1 DIABETES Anneli, Martina s daughter In better control with her pump since 2011 MY CHILD HAS TYPE 1 DIABETES Many parents whose child is diagnosed with Type 1 diabetes wonder: Why is this happening to my child?

More information

Anneli, Martina s daughter In better control with her pump since 2011 MY CHILD HAS TYPE 1 DIABETES

Anneli, Martina s daughter In better control with her pump since 2011 MY CHILD HAS TYPE 1 DIABETES Anneli, Martina s daughter In better control with her pump since 2011 MY CHILD HAS TYPE 1 DIABETES Many parents whose child is diagnosed with Type 1 diabetes wonder: Why is this happening to my child?

More information

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,

More information

Harmony Clinical Trial Medical Media Factsheet

Harmony Clinical Trial Medical Media Factsheet Overview Harmony is the global Phase III clinical trial program for Tanzeum (albiglutide), a product developed by GSK for the treatment of type 2 diabetes. The comprehensive program comprised eight individual

More information

DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study

DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study National Diabetes Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What

More information

NCT00272090. sanofi-aventis HOE901_3507. insulin glargine

NCT00272090. sanofi-aventis HOE901_3507. insulin glargine These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:

More information

Diabetes Complications

Diabetes Complications Managing Diabetes: It s s Not Easy But It s s Worth It Presenter Disclosures W. Lee Ball, Jr., OD, FAAO (1) The following personal financial relationships with commercial interests relevant to this presentation

More information

Cardiovascular Disease in Diabetes

Cardiovascular Disease in Diabetes Cardiovascular Disease in Diabetes Where Do We Stand in 2012? David M. Kendall, MD Distinguished Medical Fellow Lilly Diabetes Associate Professor of Medicine University of MInnesota Disclosure - Duality

More information

Measure #1 (NQF 0059): Diabetes: Hemoglobin A1c Poor Control National Quality Strategy Domain: Effective Clinical Care

Measure #1 (NQF 0059): Diabetes: Hemoglobin A1c Poor Control National Quality Strategy Domain: Effective Clinical Care Measure #1 (NQF 0059): Diabetes: Hemoglobin A1c Poor Control National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION: Percentage

More information

Starting patients on the V-Go Disposable Insulin Delivery Device

Starting patients on the V-Go Disposable Insulin Delivery Device Starting patients on the V-Go Disposable Insulin Delivery Device A simple guide for your practice For adult patients with Type 2 diabetes on basal insulin who need to take the next step Identify appropriate

More information

CASE B1. Newly Diagnosed T2DM in Patient with Prior MI

CASE B1. Newly Diagnosed T2DM in Patient with Prior MI Newly Diagnosed T2DM in Patient with Prior MI 1 Our case involves a gentleman with acute myocardial infarction who is newly discovered to have type 2 diabetes. 2 One question is whether anti-hyperglycemic

More information

The Lowdown on Insulin Pump Therapy - Part One

The Lowdown on Insulin Pump Therapy - Part One DIABETES TECHNOLOGY & THERAPEUTICS Volume 17, Supplement 1, 2015 ª Mary Ann Liebert, Inc. DOI: 10.1089/dia.2015.1503 ORIGINAL ARTICLE Insulin Pumps John Pickup Introduction Three of the four themes concerning

More information

Medical Policy Insulin Pumps

Medical Policy Insulin Pumps Medical Policy Insulin Pumps Document Number: 027 Authorization required Insulin Pumps & supplies Notification within 24 hours of service or next business day No Prior Authorization Not covered Pulsatile

More information

Cardiovascular Effects of Drugs to Treat Diabetes

Cardiovascular Effects of Drugs to Treat Diabetes Cardiovascular Effects of Drugs to Treat Diabetes Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical companies Clinical Trials:

More information

嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯

嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized

More information

CASE A1 Hypoglycemia in an Elderly T2DM Patient with Heart Failure

CASE A1 Hypoglycemia in an Elderly T2DM Patient with Heart Failure Hypoglycemia in an Elderly T2DM Patient with Heart Failure 1 I would like to introduce you to Sophie, an elderly patient with long-standing type 2 diabetes, who has a history of heart failure, a common

More information

Present and Future of Insulin Therapy: Research Rationale for New Insulins

Present and Future of Insulin Therapy: Research Rationale for New Insulins Present and Future of Insulin Therapy: Research Rationale for New Insulins Current insulin analogues represent an important advance over human insulins, but clinically important limitations of these agents

More information

Self-Monitoring Of Blood Glucose (SMBG)

Self-Monitoring Of Blood Glucose (SMBG) Self-Monitoring Of Blood Glucose (SMBG) Aim(s) and objective(s) It is important is to ensure that people with Diabetes are given the opportunity to self monitor their blood glucose appropriately as an

More information

Insulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks

Insulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks Background: Insulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks Final Background and Scope November 19, 2015 The Centers for Disease Control

More information

A Simplified Approach to Initiating Insulin. 4. Not meeting glycemic goals with oral hypoglycemic agents or

A Simplified Approach to Initiating Insulin. 4. Not meeting glycemic goals with oral hypoglycemic agents or A Simplified Approach to Initiating Insulin When to Start Insulin: 1. Fasting plasma glucose (FPG) levels >250 mg/dl or 2. Glycated hemoglobin (A1C) >10% or 3. Random plasma glucose consistently >300 mg/dl

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Afrezza Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization

More information

Inpatient Treatment of Diabetes

Inpatient Treatment of Diabetes Inpatient Treatment of Diabetes Alan J. Conrad, MD Medical Director Diabetes Services EVP, Physician Alignment Diabetes Symposium November 12, 2015 Objectives Explain Palomar Health goals for inpatient

More information

Clinical and cost-effectiveness of continuous subcutaneous insulin infusion therapy in diabetes.

Clinical and cost-effectiveness of continuous subcutaneous insulin infusion therapy in diabetes. PROTOCOL Clinical and cost-effectiveness of continuous subcutaneous insulin infusion therapy in diabetes. A. This the revised protocol (April 2002) B. Review team Contact for correspondence: Dr Jill Colquitt

More information

The Economic Benefit of Public Funding of Insulin Pumps in. New Brunswick

The Economic Benefit of Public Funding of Insulin Pumps in. New Brunswick The Economic Benefit of Public Funding of Insulin Pumps in New Brunswick Introduction Diabetes is a chronic, often debilitating and sometimes fatal disease, in which the body either cannot produce insulin

More information

Causes, incidence, and risk factors

Causes, incidence, and risk factors Causes, incidence, and risk factors Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both. To understand diabetes,

More information

Using a Flow Sheet to Improve Performance in Treatment of Elderly Patients With Type 2 Diabetes

Using a Flow Sheet to Improve Performance in Treatment of Elderly Patients With Type 2 Diabetes Special Series: AAFP Award-winning Research Papers Vol. 31, No. 5 331 Using a Flow Sheet to Improve Performance in Treatment of Elderly Patients With Type 2 Diabetes Gary Ruoff, MD; Lynn S. Gray, MD, MPH

More information

Diabetes and Technology. Disclosures Certified Insulin Pump Trainer for: Animas Medtronic Diabetes Omnipod. Rebecca Ray, MSN, APRN, FNP-C

Diabetes and Technology. Disclosures Certified Insulin Pump Trainer for: Animas Medtronic Diabetes Omnipod. Rebecca Ray, MSN, APRN, FNP-C Diabetes and Technology Rebecca Ray, MSN, APRN, FNP-C Insulin Pump Therapy and Continuous Glucose Monitoring In Patients with Type 2 Diabetes Page 1 Disclosures Certified Insulin Pump Trainer for: Animas

More information

CHAPTER V DISCUSSION. normal life provided they keep their diabetes under control. Life style modifications

CHAPTER V DISCUSSION. normal life provided they keep their diabetes under control. Life style modifications CHAPTER V DISCUSSION Background Diabetes mellitus is a chronic condition but people with diabetes can lead a normal life provided they keep their diabetes under control. Life style modifications (LSM)

More information

The basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE

The basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE The basal plus strategy Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE ADA/EASD guidelines recommend use of basal insulin as early as the second step

More information

Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes

Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center

More information

Imagine a world... Believe in better control. MiniMed Veo Paradigm System Questions and Answers About Insulin Pumping

Imagine a world... Believe in better control. MiniMed Veo Paradigm System Questions and Answers About Insulin Pumping Imagine a world... Believe in better control MiniMed Veo Paradigm System Questions and Answers About Insulin Pumping 1 Imagine a world... Where you can exercise whenever you want and not have to carb load

More information

Diabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus

Diabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus Melissa Meredith M.D. Diabetes mellitus is a group of metabolic diseases characterized by high blood glucose resulting from defects in insulin secretion, insulin action, or both Diabetes is a chronic,

More information

Novel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety

Novel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety Novel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety Anders Svensson MD, PhD Head of Global Clinical Development Metabolism, F Hoffmann LaRoche Ltd. Basel, Switzerland Overview of

More information

Improving drug prescription in elderly diabetic patients. FRANCESC FORMIGA Hospital Universitari de Bellvitge

Improving drug prescription in elderly diabetic patients. FRANCESC FORMIGA Hospital Universitari de Bellvitge Improving drug prescription in elderly diabetic patients FRANCESC FORMIGA Hospital Universitari de Bellvitge High prevalence, but also increases the incidence. The older the patients, the higher the percentages

More information

Imagine a world... Believe in better control. MiniMed Veo Paradigm System

Imagine a world... Believe in better control. MiniMed Veo Paradigm System Imagine a world... Believe in better control MiniMed Veo Paradigm System 1 Imagine a world... Where you can exercise whenever you want and not have to carb load or worry about hypos. R Where you can eat

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PC - Apidra, Levemir Therapeutic Class: Hormones and Synthetic Substitutes Therapeutic Sub-Class: Antidiabetic Agents Client: CA, CO, NV, OK, OR, WA and AZ Approval

More information

When and how to start insulin: strategies for success in type 2 diabetes

When and how to start insulin: strategies for success in type 2 diabetes 1 When and how to start insulin: strategies for success in type diabetes Treatment of type diabetes in 199: with each step treatment gets more complex Bruce H.R. Wolffenbuttel, MD PhD Professor of Endocrinology

More information

Understanding diabetes Do the recent trials help?

Understanding diabetes Do the recent trials help? Understanding diabetes Do the recent trials help? Dr Geoffrey Robb Consultant Physician and Diabetologist CMO RGA UK Services and Partnership Assurance AMUS 25 th March 2010 The security of experience.

More information

Adherence to insulin therapy at a tertiary care diabetes center in South India

Adherence to insulin therapy at a tertiary care diabetes center in South India Original Article: Adherence to insulin therapy at a tertiary care diabetes center in South India M.S. Raut, J. Balasubramanian, R.M. Anjana, R Unnikrishnan, *V. Mohan Abstract To assess patient adherence

More information

QUESTION 3. HOW SHOULD THE DATA AND REPORTING BE INTERPRETED?

QUESTION 3. HOW SHOULD THE DATA AND REPORTING BE INTERPRETED? QUESTION 3. HOW SHOULD THE DATA AND REPORTING BE INTERPRETED? AACE/ACE CGM Consensus Conference: Medical, Scientific, Professional, and Educational Societies Question 3a. Are there standard metrics that

More information

Primary prevention of chronic kidney disease: managing diabetes mellitus to reduce the risk of progression to CKD

Primary prevention of chronic kidney disease: managing diabetes mellitus to reduce the risk of progression to CKD Primary prevention of chronic kidney disease: managing diabetes mellitus to reduce the risk of progression to CKD Date written: July 2012 Author: Kate Wiggins, Graeme Turner, David Johnson GUIDELINES We

More information

Alternative method for delivering insulin using continuous subcutaneous insulin infusion (CSII) open loop system

Alternative method for delivering insulin using continuous subcutaneous insulin infusion (CSII) open loop system ISHP Spring CE Conference April 12, 2015 St. Luke s Medical Center Randi Lynn Griffiths, PharmD Clinical outpatient pharmacist Boise VA Medical Center Boise, Idaho Alternative method for delivering insulin

More information

The Quantified Self on Steroids: Innovation in Devices, Pumps and Monitors

The Quantified Self on Steroids: Innovation in Devices, Pumps and Monitors The Quantified Self on Steroids: Innovation in Devices, Pumps and Monitors Howard A. Wolpert, MD 1 Diabetes is different to many other conditions Patient/Self Managed 2 To achieve the therapeutic goals

More information

Insulin myths and facts

Insulin myths and facts london medicines evaluation network Insulin myths and facts Statement 1 Insulin is the last resort for patients with Type 2 diabetes After initial metformin and sulfonylurea therapy, NICE and SIGN suggest

More information

linagliptin, 5mg film-coated tablet (Trajenta ) SMC No. (746/11) Boehringer Ingelheim / Eli Lilly and Company Ltd

linagliptin, 5mg film-coated tablet (Trajenta ) SMC No. (746/11) Boehringer Ingelheim / Eli Lilly and Company Ltd linagliptin, 5mg film-coated tablet (Trajenta ) SMC No. (746/11) Boehringer Ingelheim / Eli Lilly and Company Ltd 09 December 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of

More information

Treatment Approaches to Diabetes

Treatment Approaches to Diabetes Treatment Approaches to Diabetes Dr. Sarah Swofford, MD, MSPH & Marilee Bomar, GCNS, CDE Quick Overview Lifestyle Oral meds Injectables not insulin Insulin Summary 1 Lifestyle & DM Getting to the point

More information

SHORT CLINICAL GUIDELINE SCOPE

SHORT CLINICAL GUIDELINE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SHORT CLINICAL GUIDELINE SCOPE 1 Guideline title Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes 1.1 Short title Type 2

More information

BACKGROUND. ADA and the European Association recently issued a consensus algorithm for management of type 2 diabetes

BACKGROUND. ADA and the European Association recently issued a consensus algorithm for management of type 2 diabetes BACKGROUND More than 25% of people with diabetes take insulin ADA and the European Association recently issued a consensus algorithm for management of type 2 diabetes Insulin identified as the most effective

More information

Medical Coverage Policy Glucose Monitoring Systems sad

Medical Coverage Policy Glucose Monitoring Systems sad Medical Coverage Policy Glucose Monitoring Systems sad EFFECTIVE DATE: 03 03 2009 POLICY LAST UPDATED: 01 17 2012 OVERVIEW This policy addresses several methods of monitoring blood glucose: the glucometer,

More information

Efficacy, safety and preference study of a insulin pen PDS290 vs. a Novo Nordisk marketed insulin pen in diabetics

Efficacy, safety and preference study of a insulin pen PDS290 vs. a Novo Nordisk marketed insulin pen in diabetics Efficacy, safety and preference study of a insulin pen PDS290 vs. a Novo Nordisk marketed insulin pen in diabetics This trial is conducted in the United States of America (USA). The aim of this clinical

More information

Practical Applications of Insulin Pump Therapy in Type 2 Diabetes

Practical Applications of Insulin Pump Therapy in Type 2 Diabetes Practical Applications of Insulin Pump Therapy in Type 2 Diabetes Wendy Lane, MD For a CME/CEU version of this article please go to www.namcp.org/cmeonline.htm, and then click the activity title. Summary

More information

The Economic Benefit of Public Funding of Insulin Pumps in Prince Edward Island

The Economic Benefit of Public Funding of Insulin Pumps in Prince Edward Island The Economic Benefit of Public Funding of Insulin Pumps in Prince Edward Island Executive Summary Every day, Prince Edward Islanders living with type 1 diabetes take insulin to live. Many deliver insulin

More information

Comparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians

Comparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians Clinician Research Summary Diabetes Type 2 Diabetes Comparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians A systematic review of 166 clinical studies published between

More information

INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT

INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT APIRADEE SRIWIJITKAMOL DIVISION OF ENDOCRINOLOGY AND METABOLISM DEPARTMENT OF MEDICINE FACULTY OF MEDICINE SIRIRAJ HOSPITOL QUESTION 1 1. ท านเคยเป นแพทย

More information

Criteria: CWQI HCS-123 (This criteria is consistent with CMS guidelines for External Infusion Insulin Pumps)

Criteria: CWQI HCS-123 (This criteria is consistent with CMS guidelines for External Infusion Insulin Pumps) Moda Health Plan, Inc. Medical Necessity Criteria Subject: Origination Date: 05/15 Revision Date(s): 05/2015 Developed By: Medical Criteria Committee 06/24/2015 External Infusion Insulin Pumps Page 1 of

More information

The MiniMed Paradigm Veo System

The MiniMed Paradigm Veo System The MiniMed Paradigm Veo System Live More, Worry Less First CGM-ready insulin pump with automatic insulin shut-off mechanism www.medtronic-diabetes.co.uk The freedom you deserve Round-the clock support

More information

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University

More information

www.leicestershirediabetes.org.uk

www.leicestershirediabetes.org.uk www.leicestershirediabetes.org.uk Diabetes Care UHL Haemoglobin A1c Testing (HbA1c) A guide for patients and healthcare professionals Haemoglobin A1c Testing (HbA1c) Introduction The Diabetes Team have

More information

Insulin Pump Therapy in Australia. The Case for Action

Insulin Pump Therapy in Australia. The Case for Action Insulin Pump Therapy in Australia The Case for Action This report has been prepared by Diabetes Australia. Diabetes Australia is the national body for all people affected by all types of diabetes and those

More information

Sanofi Reports Positive Phase 3 Results for Toujeo (insulin glargine [rdna origin] injection, 300 U/mL)

Sanofi Reports Positive Phase 3 Results for Toujeo (insulin glargine [rdna origin] injection, 300 U/mL) PRESS RELEASE Sanofi Reports Positive Phase 3 Results for Toujeo (insulin glargine [rdna origin] injection, 300 U/mL) Meta-analysis of three late-stage trials in people with type 2 diabetes shows decreases

More information

Sponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.

Sponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational. Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,

More information

Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care

Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

More information

Therapy Insulin Practical guide to Health Care Providers Quick Reference F Diabetes Mellitus in Type 2

Therapy Insulin Practical guide to Health Care Providers Quick Reference F Diabetes Mellitus in Type 2 Ministry of Health, Malaysia 2010 First published March 2011 Perkhidmatan Diabetes dan Endokrinologi Kementerian Kesihatan Malaysia Practical guide to Insulin Therapy in Type 2 Diabetes Mellitus Quick

More information

MEDICATION THERAPY ADHERENCE CLINIC : DIABETES

MEDICATION THERAPY ADHERENCE CLINIC : DIABETES MEDICATION THERAPY ADHERENCE CLINIC : DIABETES PHARMACEUTICAL SERVICES DIVISION MINISTRY OF HEALTH MALAYSIA First Edition, 2010 Pharmaceutical Services Division Ministry of Health, Malaysia ALL RIGHT RESERVED

More information

trends in the treatment of Diabetes type 2 - New classes of antidiabetic drugs. IAIM, 2015; 2(4): 223-

trends in the treatment of Diabetes type 2 - New classes of antidiabetic drugs. IAIM, 2015; 2(4): 223- Review Article Pharmacological trends in the treatment of Diabetes type 2 - New classes of antidiabetic Silvia Mihailova 1*, Antoaneta Tsvetkova 1, Anna Todorova 2 1 Assistant Pharmacist, Education and

More information

Updates for your practice March, 2013. Vol 2, Issue 14 TLALELETSO. Managing Complicated Diabetes

Updates for your practice March, 2013. Vol 2, Issue 14 TLALELETSO. Managing Complicated Diabetes dates for your practice March, 2013. Vol 2, Issue 14 TLALELETSO Managing Complicated Diabetes Diabetes is increasingly common Managing diabetes and working as part of a multidisciplinary team is essential

More information

Statins and Risk for Diabetes Mellitus. Background

Statins and Risk for Diabetes Mellitus. Background Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration

More information

Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes

Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim

More information

How to get the most of your blood glucose readings

How to get the most of your blood glucose readings How to get the most of your blood glucose readings Page 3 Page 4 Page 5 Page 5 Page 7 Page 7 Page 8 Page 9 Page 10 Page 11 1 Why you should do blood glucose monitoring? 2 How to do it correctly? 3 Who

More information

Insulin Algorithm for Type 2 Diabetes Mellitus in Children and Adults

Insulin Algorithm for Type 2 Diabetes Mellitus in Children and Adults Insulin Algorithm for Type 2 Diabetes Mellitus in Children and Adults Stock # 45-11647 Revised 10/28/10 Glycemic Goals 1,2 Individualize goal based on patient risk factors A1c 6%

More information

Jill Malcolm, Karen Moir

Jill Malcolm, Karen Moir Evaluation of Fife- DICE: Type 2 diabetes insulin conversion Article points 1. Fife-DICE is an insulin conversion group education programme. 2. People with greater than 7.5% on maximum oral therapy are

More information

British Columbia Pharmacy Association (BCPhA) Clinical Service Proposal Self-Monitoring of Blood Glucose in Type 2 Diabetes

British Columbia Pharmacy Association (BCPhA) Clinical Service Proposal Self-Monitoring of Blood Glucose in Type 2 Diabetes British Columbia Pharmacy Association (BCPhA) Clinical Service Proposal Self-Monitoring of Blood Glucose in Type 2 Diabetes Introduction Self-monitoring of blood glucose (SMBG) is in widespread use among

More information

SARASOTA MEMORIAL HOSPITAL

SARASOTA MEMORIAL HOSPITAL SARASOTA MEMORIAL HOSPITAL TITLE: NURSING PROCEDURE MANAGEMENT OF PATIENT S OWN INSULIN PUMP/CONTINUOUS SUBCUTANEOUS INSULIN INFUSION PUMP (dia13) DATE: REVIEWED: PAGES: 08/84 10/15 1 of 7 PS1094 ISSUED

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium insulin glulisine for subcutaneous injection 100 units/ml (Apidra ) No. (298/06) Sanofi Aventis 4 August 2006 The Scottish Medicines Consortium (SMC) has completed its assessment

More information

TYPE 2 DIABETES SEQUENTIAL INSULIN STRATEGIES

TYPE 2 DIABETES SEQUENTIAL INSULIN STRATEGIES TYPE 2 DIABETES SEQUENTIAL INSULIN STRATEGIES Non-insulin regimes Basal insulin only (usually with oral agents) Number of injections 1 Regimen complexity Low Basal insulin +1 meal-time rapidacting insulin

More information

PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain

PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain P a g e 1 PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain Clinical Phase 4 Study Centers Study Period 25 U.S. sites identified and reviewed by the Steering Committee and Contract

More information

Insulin Pump Therapy

Insulin Pump Therapy CHILDREN S SERVICES Insulin Pump Therapy These guidelines are not intended for starting a patient on an insulin pump. They are intended to give staff not part of the diabetic team information regarding

More information

tips Insulin Pump Users 1 Early detection of insulin deprivation in continuous subcutaneous 2 Population Study of Pediatric Ketoacidosis in Sweden:

tips Insulin Pump Users 1 Early detection of insulin deprivation in continuous subcutaneous 2 Population Study of Pediatric Ketoacidosis in Sweden: tips Top International Publications Selection Insulin Pump Users Early detection of insulin deprivation in continuous subcutaneous insulin infusion-treated Patients with TD Population Study of Pediatric

More information

Insulin Pump Therapy for Type 1 Diabetes

Insulin Pump Therapy for Type 1 Diabetes Insulin Pump Therapy for Type 1 Diabetes Aim(s) and objective(s) This guideline has been developed to describe which patients with Type 1 Diabetes should be referred for assessment for insulin pump therapy

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Is what you know about INSULIN PUMP THERAPY. This educational resource is provided by Medtronic MiniMed, Inc.

Is what you know about INSULIN PUMP THERAPY. This educational resource is provided by Medtronic MiniMed, Inc. Is what you know about INSULIN PUMP THERAPY MYTH or? This educational resource is provided by Medtronic MiniMed, Inc. You have to know a lot about technology to learn to use a pump Interacting with your

More information

Insulin pump therapy aiming for better blood glucose control in people with type 1 diabetes

Insulin pump therapy aiming for better blood glucose control in people with type 1 diabetes Insulin pump therapy aiming for better blood glucose control in people with type 1 diabetes The Guy s and St Thomas NHS Foundation Trust insulin pump service is provided by a multidisciplinary team consisting

More information

EASD/ADA 2015 Highlights- insulin. Dr Jarl Hellman

EASD/ADA 2015 Highlights- insulin. Dr Jarl Hellman EASD/ADA 2015 Highlights- insulin Dr Jarl Hellman Innehåll NPH Epidemiologi Nya insuliner Basinsulinets bäste vän exklusive hund och UKPDS? G.B Bolli Hypoglykemi - NPH Exogenous insulin and risk of all-cause

More information

INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco

INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco CLINICAL RECOGNITION Background: Appropriate inpatient glycemic

More information

Efficacy and Safety of Insulin Aspart in Patients with Type 1 Diabetes Mellitus

Efficacy and Safety of Insulin Aspart in Patients with Type 1 Diabetes Mellitus Clin Pediatr Endocrinol 2002; 11(2), 87-92 Copyright 2002 by The Japanese Society for Pediatric Endocrinology Original Efficacy and Safety of Insulin Aspart in Patients with Type 1 Diabetes Mellitus Toshikazu

More information

National Evidence Based Guideline for Blood Glucose Control in Type 2 Diabetes

National Evidence Based Guideline for Blood Glucose Control in Type 2 Diabetes National Evidence Based Guideline for Blood Glucose Control in Type 2 Diabetes Prepared by: The Boden Institute of Obesity, Nutrition and Exercise The University of Sydney In collaboration with: The Diabetes

More information

2. What Should Advocates Know About Diabetes? O

2. What Should Advocates Know About Diabetes? O 2. What Should Advocates Know About Diabetes? O ften a school district s failure to properly address the needs of a student with diabetes is due not to bad faith, but to ignorance or a lack of accurate

More information

Inpatient Guidelines: Insulin Infusion Pump Management

Inpatient Guidelines: Insulin Infusion Pump Management Inpatient Guidelines: Insulin Infusion Pump Management Developed by the Statewide Diabetes Clinical Network Steering Committee July 2012 Clinical Access and Redesign Unit Table of Contents Purpose...4

More information

CARDIAC SURGERY INTRAVENOUS INSULIN PROTOCOL PHYSICIAN ORDERS INDICATIONS EXCLUSIONS. Insulin allergy

CARDIAC SURGERY INTRAVENOUS INSULIN PROTOCOL PHYSICIAN ORDERS INDICATIONS EXCLUSIONS. Insulin allergy Page 1 of 5 INDICATIONS EXCLUSIONS 2 consecutive blood glucose measurements greater than 110 mg per dl AND NPO with a continuous caloric source AND Diagnosis of : Cardio-thoracic Surgery NOTE: This protocol

More information

Workshop A Tara Kadis

Workshop A Tara Kadis Workshop A Tara Kadis Considerations/barriers in decision making about insulin verses GLP-1 use in people with type 2 diabetes Which Insulin regimes should we consider? Diabetes is a progressive multi-system

More information

Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both.

Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both. Diabetes Definition Diabetes is a chronic (lifelong) disease marked by high levels of sugar in the blood. Causes Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused

More information

Insulin or GLP1 How to make this choice in Practice. Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust

Insulin or GLP1 How to make this choice in Practice. Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust Insulin or GLP1 How to make this choice in Practice Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust Workshop Over View Considerations/barriers to treatments in type 2

More information

Insulin therapy in various type 1 diabetes patients workshop

Insulin therapy in various type 1 diabetes patients workshop Insulin therapy in various type 1 diabetes patients workshop Bruce H.R. Wolffenbuttel, MD PhD Dept of Endocrinology, UMC Groningen website: www.umcg.net & www.gmed.nl Twitter: @bhrw Case no. 1 Male of

More information

Use of Glycated Hemoglobin and Microalbuminuria in the Monitoring of Diabetes Mellitus

Use of Glycated Hemoglobin and Microalbuminuria in the Monitoring of Diabetes Mellitus Agency for Healthcare Research and Quality Evidence Report/Technology Assessment Number 84 Use of Glycated Hemoglobin and Microalbuminuria in the Monitoring of Diabetes Mellitus Summary Overview Clinical

More information

Self-Monitoring of Blood Glucose (SMBG)

Self-Monitoring of Blood Glucose (SMBG) Self-Monitoring of Blood Glucose (SMBG) Marie Russell, MD, MPH Deputy Chief Medical Officer Phoenix Area Indian Health Service IHS Division of Diabetes September 2013 Objectives History of SMBG Use and

More information

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,

More information

CSII (CONTINUOUS SUBCUTANEOUS INSULIN INFUSION) AND INPATIENT ADMISSION

CSII (CONTINUOUS SUBCUTANEOUS INSULIN INFUSION) AND INPATIENT ADMISSION CSII (CONTINUOUS SUBCUTANEOUS INSULIN INFUSION) AND INPATIENT ADMISSION Goals of Inpatient Glucose Management Avoid Hypoglycemia (Serum glucose

More information

Insulin Pump Therapy Education Protocol

Insulin Pump Therapy Education Protocol Insulin Pump Therapy Education Protocol Considerations for Developing Your Own Best Practices 9402474-011 1 Objective Provide an overview of the importance of developing an insulin pump therapy education

More information